← Leaderboards
Mahmoud Kiaei
Weill Medical Coll Of Cornell Univ
$963,120
Attributed
$963,120
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $223.5K · FY2009–18$250K$187.5K$125K$62.5K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$963,120 · 3
By mechanism
R21$814,120 · 2
R03$149,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Bobby Thomas$7,388,450
- Ashutosh K Tewari$1,328,463
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantAmyotrophic Lateral SclerosisTransgenic MiceNerve DegenerationSpinal CordMouse ModelMitochondriaNeuronsNeuron LossAnimal ModelIn VivoPerformanceGenesProteinsBody Weight DecreasedFamilial Amyotrophic Lateral SclerosisMotorMotor NeuronsResearch StudyPharmaceutical PreparationsNeuroinflammationCessation Of LifeAstrocytesMolecular
Grant awards (7)
Alpha-Tubulin Mutation and Motor Neuron Disease$74,500
R03 · FY2018 · NS · contact PI
Alpha-Tubulin Mutation and Motor Neuron Disease$74,500
R03 · FY2017 · NS · contact PI
Development of a New ALS Mouse Model that Targets Profilin1 and Actin Filaments$186,250
R21 · FY2016 · NS · contact PI
Development of a New ALS Mouse Model that Targets Profilin1 and Actin Filaments$223,500
R21 · FY2015 · NS · contact PI
NRF2/ARE PATHWAY AS A THERAPEUTIC TARGET FOR AMYOTROPHIC LATERAL SCLEROSIS$132,378
R21 · FY2010 · NS · contact PI
NRF2/ARE PATHWAY AS A THERAPEUTIC TARGET FOR AMYOTROPHIC LATERAL SCLEROSIS$50,617
R21 · FY2010 · NS · contact PI
NRF2/ARE PATHWAY AS A THERAPEUTIC TARGET FOR AMYOTROPHIC LATERAL SCLEROSIS$221,375
R21 · FY2009 · NS · contact PI